缺氧诱导因子-1α参与肝纤维化形成机制研究进展

doi:10.3969/j.issn.1672-5069.2021.01.038

Abstract

Abstract: Objective Liver fibrosis is caused by excessive deposition of extracellular matrix in liver tissues due to repeated liver injuries and hypoxia injury is a part of liver injury. Hypoxia inducible factor-1 α (HIF-1α) is a key transcription factor in response to hypoxia stress, and its expression in liver fibrotic tissues and activated HSCs is significantly increased. At present, a number of HIF-1α dependent genes and related signaling pathways have been studied to confirm that the changes of these genes and pathways are related to the development of liver fibrosis, suggesting that HIF-1α may play a key role in liver fibrosis. In this review, the mechanism of HIF-1α-related signaling pathway in the development of liver fibrosis and the synthesis and degradation of HIF-1α from the upstream are described.

Key words: Liver fibrosis, Hypoxia inducible factor-1α, Therapeutic target

Liu Ruiqing,Yuan Xiaopeng. Mechanism of hypoxia inducible factor-1α involving in liver fibrosis[J]. Journal of Practical Hepatology, 2021, 24(1): 145-148.

References

[1] Roth K J, Copple B L. Role of hypoxia-inducible factors in the development of liver fibrosis. Cell Mol Gastroenterol Hepatol, 2015, 1(6): 589-597.
[2] Bataller R, Brenner D A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis, 2001, 21(3): 437-451.
[3] Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev, 2008, 88(1): 125-172.
[4] Moon J O, Welch T P, Gonzalez F J, et al. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol, 2009, 296(3): G582-G592.
[5] Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology, 2012, 55(2): 622-633.
[6] 杜静,赵秋,谷华,等. 缺氧诱导因子-1α及其靶基因在人肝癌HepG2细胞中的表达和意义. 中华肝脏病杂志, 2006,12(8): 607-609.
[7] Sparkenbaugh E M, Saini Y, Greenwood K K, et al. The role of hypoxia-inducible factor-1alpha in acetaminophen hepatotoxicity. J Pharmacol Exp Ther, 2011, 338(2): 492-502.
[8] Copple B L, Bai S, Burgoon L D, et al. Hypoxia-inducible factor-1alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int, 2011, 31(2): 230-244.
[9] Yang F, Luo L, Zhu Z D, et al. Chlorogenic acid inhibits liver fibrosis by blocking the miR-21-regulated TGF-beta1/Smad7 signaling pathway in vitro and in vivo. Front Pharmacol, 2017, 8: 929.
[10] Carmeliet P. Angiogenesis in life, disease and medicine. Nature, 2005, 438(7070): 932-936.
[11] 姚登福,孟宪镛. 肝细胞癌变过程中血管内皮生长因子异常表达及其机制的研究进展. 中华肝脏病杂志, 2001,9(3): 187-188.
[12] Qu K, Yan Z, Wu Y, et al. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1alpha dependent pathway in hepatocellular carcinoma. J Gastroenterol Hepatol, 2015, 30(5): 925-932.
[13] Chen D, Tian W, Li Y, et al. Osteoblast-specific transcription factor Osterix (Osx) and HIF-1alpha cooperatively regulate gene expression of vascular endothelial growth factor (VEGF). Biochem Biophys Res Commun, 2012, 424(1): 176-181.
[14] Weijts B G, Bakker W J, Cornelissen P W, et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1. EMBO J, 2012, 31(19): 3871-3884.
[15] Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer, 2013, 109(1): 83-91.
[16] Li Z, Ding Q, Ling L P, et al. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase. World J Gastroenterol, 2018, 24(7): 819-832.
[17] Zhang F, Hao M, Jin H, et al. Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis. Br J Pharmacol, 2017, 174(5): 409-423.
[18] Gao J H, Wen S L, Feng S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis, 2016, 19(4): 501-511.
[19] Ni H M, Williams J A, Yang H, et al. Targeting autophagy for the treatment of liver diseases. Pharmacol Res, 2012, 66(6): 463-474.
[20] Deng J, Huang Q, Wang Y, et al. Hypoxia-inducible factor-1alpha regulates autophagy to activate hepatic stellate cells. Biochem Biophys Res Commun, 2014, 454(2): 328-334.
[21] Zhou X, Sun H, Chen H, et al. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res, 2010, 70(10): 4214-4221.
[22] Hong F, Wan L, Liu J, et al. Histone methylation regulates Hif-1 signaling cascade in activation of hepatic stellate cells. FEBS Open Bio, 2018, 8(3): 406-415.
[23] Ara A I, Xia M, Ramani K, et al. S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. Hepatology, 2008, 47(5): 1655-1666.
[24] Laplante M, Sabatini D M. mTOR signaling in growth control and disease. Cell, 2012, 149(2): 274-293.
[25] Zhao Y, Ma X, Wang J, et al. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1alpha through mTOR-dependent pathway. Fitoterapia, 2014, 99: 318-327.
[26] Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 2008, 453(7196): 807-811.
[27] Moczydlowska J, Miltyk W, Hermanowicz A, et al. HIF-1 alpha as a key factor in bile duct ligation-induced liver fibrosis in rats. J Invest Surg, 2017, 30(1): 41-46.
[28] Sutton K M, Hayat S, Chau N M, et al. Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene, 2007, 26(27): 3920-3929.
[29] Wang Y, Huang Y, Guan F, et al. Hypoxia-inducible factor-1alpha and MAPK co-regulate activation of hepatic stellate cells upon hypoxia stimulation. PLoS One, 2013, 8(9): e74051.
[30] Copple B L, Kaska S, Wentling C. Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. J Pharmacol Exp Ther, 2012, 341(2): 307-316.
[31] Zhao Y, Ma X, Wang J, et al. Curcumin protects against CCl₄-induced liver fibrosis in rats by inhibiting HIF-1alpha through an ERK-dependent pathway. Molecules, 2014, 19(11): 18767-18780.
[32] Chouchani E T, Pell V R, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature, 2014, 515(7527): 431-435.
[33] She L, Xu D, Wang Z, et al. Curcumin inhibits hepatic stellate cell activation via suppression of succinate-associated HIF-1alpha induction. Mol Cell Endocrinol, 2018, 476: 129-138.
[34] Jaakkola P, Mole D R, Tian Y M, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 2001, 292(5516): 468-472.
[35] Mills E L, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell, 2016, 167(2): 457-470.
[36] Wang J, Lu Z, Xu Z, et al. Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease. Sci Rep, 2017, 7: 41038.
[37] Zhang C, Bian M, Chen X, et al. Oroxylin A prevents angiogenesis of LSECs in liver fibrosis via inhibition of YAP/HIF-1alpha signaling. J Cell Biochem, 2018, 119(2): 2258-2268.
[38] Deleve L D. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology, 2015, 61(5): 1740-1746.
[39] Ma B, Chen Y, Chen L, et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat Cell Biol, 2015, 17(1): 95-103.

Mechanism of hypoxia inducible factor-1α involving in liver fibrosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Song Yeyu, Fan Jiangao. Diagnosis and treatment of sarcopenic obesity with fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 149-152.
[2]	Zhang Hao, Chang Jiandong, Chen Xiaoyan.. Diagnostic value of ultrasonic elastography combined with serological indexes in evaluation of liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2020, 23(5): 642-645.
[3]	Li Na, Zheng Shaoqiu, Zhao Shousong. Application of FibroScan, APRI,FIB-4 and GPR in prediction of esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(4): 560-563.
[4]	Chen Lili, Fu Maoxiong, Meng Xubiao, et al. Clinical value of fasting C-peptide in assessing the progression of liver fibrosis in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2020, 23(1): 38-41.
[5]	Sun Hongju, Wang Yanyan, Xu Congcong, et al. Efficacy of tiopronin and metoprolol combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2020, 23(1): 54-57.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[8]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[9]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[10]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[11]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[12]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[13]	Yusup Tursun, Zhao Yanxia.. Establishment of low-dose diethylnitrosamine-induced liver fibrosis model in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 33-36.
[14]	Guo Xiaoxia, Guo Beiting, Kong Xianglu.. Effects of splenectomy on hepatic fibrosis in mice with poly I:C-induced primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 837-841.
[15]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.